Men's Health

Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.

In its push to close the loophole on physician self-referral for prostate cancer treatment, the American Society for Radiation Oncology now has what some may call an unlikely ally.

Abiraterone acetate (ZYTIGA) significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone, the authors of a multicenter study reported.

Short-term hormone therapy appears to produce outcomes that are as favorable as those for long-term therapy in men with intermediate-risk prostate cancer, according to the results of two studies from the Radiation Therapy Oncology Group.

Toxic chemicals in the environment harm our ability to reproduce and are associated with poor semen quality and prostate cancer, among other long-term health problems, according to the American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine.

The American Society for Radiation Oncology and the American Academy of Family Physicians have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to a recent study.

New research shows a significant decrease in PSA screening by primary care physicians since the release of the United States Preventive Services Task Force recommendation against screening in May 2012.

Outcomes following salvage radiation therapy after recurrent prostate cancer in a racially mixed cohort are no better when it’s started at a PSA level

Regular use of aspirin in the year before a diagnosis of stage I-III prostate cancer is associated with a reduction in prostate cancer-specific mortality, say Irish researchers.

African-American men are more influenced by convenience than are Caucasian men in their choice of treatment for early-stage prostate cancer, according to a recent study.

New therapies that are extending survival of men with metastatic castration-resistant prostate cancer may also be contributing to an increasing trend for the development of non-osseous metastatic disease in these patients, according to a recent study.

Researchers say a cooling device can reduce local inflammation and shorten time to continence-and even prevent permanent incontinence-in patients who undergo robot-assisted radical prostatectomy.

Insufficient estrogen levels in men may be at least partially to blame for symptoms that are often attributed to hypogonadism, according to a recently published study.

In an attempt to clarify what it calls conflicting guideline statements on prostate cancer screening from various organizations, the Large Urology Group Practice Association has issued its own position on the use of the PSA test as a screening tool.

The FDA has authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with BPH.

In this case, the patient tried to keep the observing urologist in the case as another source of payment by claiming a physician-patient relationship existed, thus establishing he had a legal duty to ensure the care was within the accepted standard.

Some urologists are seeing more younger men for erectile dysfunction than they have in the past, the reasons for which appear to be multi-factorial.

Two California compounding pharmacies have announced voluntary recalls of testosterone products.

A recent study has linked genetic mutations to an increased risk of developing prostate cancer.

Even as the debate over the U.S. Preventive Services Task Force’s grade D recommendation for PSA screening continues, patients made their feelings clear about the recommendation in a recent survey.

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, researchers reported.

For men aged 50–69 years, PSA testing reduces prostate cancer-specific mortality and the incidence of metastatic disease, according to a new multinational consensus statement on early detection of prostate cancer, which also calls for prostate cancer diagnosis to be unlinked from treatment for the disease.

Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.

Epigenetic profiling of prostate biopsies significantly improved the accuracy of predicting cancer in men with negative results, according to a late-breaking abstract presented at the AUA annual meeting in San Diego.

In a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.

A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.

Combining a prostate cancer gene assay with standard risk-stratification factors substantially increased information to guide decision making about active surveillance, a validation study of the assay showed.

Findings from a meta-analysis, including data from five independent patient cohorts, show that a novel genetic test is a powerful prognostic predictor of prostate cancer outcome across diverse clinical settings.

The latest products and services from neoSurgical, Wiley-Blackwell, iURO, and USARAD.com.